{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:22:17Z","timestamp":1771550537865,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2-TR-002385"],"award-info":[{"award-number":["KL2-TR-002385"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.gore.2021.100795","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T12:44:38Z","timestamp":1621946678000},"page":"100795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-028X","authenticated-orcid":false,"given":"Nora","family":"Badiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3633-4742","authenticated-orcid":false,"given":"Corbyn M.","family":"Nchako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa K.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.gore.2021.100795_b0005","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.gore.2021.100795_b0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2009.12.023","article-title":"Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?","volume":"117","author":"Cass","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2021.100795_b0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2021.100795_b0020","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol."},{"issue":"23","key":"10.1016\/j.gore.2021.100795_b0025","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.gore.2021.100795_b0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"issue":"3","key":"10.1016\/j.gore.2021.100795_b0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/AOG.0000000000003702","article-title":"Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review","volume":"135","author":"Piedimonte","year":"2020","journal-title":"Obstet Gynecol."},{"issue":"2","key":"10.1016\/j.gore.2021.100795_b0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1701-2163(15)30659-9","article-title":"The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift","volume":"36","author":"Reade","year":"2014","journal-title":"J Obstet Gynaecol Can."},{"issue":"11","key":"10.1016\/j.gore.2021.100795_b0045","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol."},{"issue":"13","key":"10.1016\/j.gore.2021.100795_b0050","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","article-title":"Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer","volume":"121","author":"Walker","year":"2015","journal-title":"Cancer."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578921000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578921000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:56:42Z","timestamp":1762480602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578921000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":10,"alternative-id":["S2352578921000990"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2021.100795","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2021.100795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100795"}}